A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2015; you can also visit the original URL.
The file type is application/pdf
.
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
2015
Breast Cancer Research
Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the prevalence of skeletal-related events including fractures and hypercalcemia. In the adjuvant setting, BPs can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence. In
doi:10.1186/s13058-015-0634-8
pmid:26328589
pmcid:PMC4557314
fatcat:lgxua3zbsbewpko5aldfha5ska